Trial Search Results

Understanding How Ketamine Brings About Rapid Improvement in OCD

The purpose of this study is to understand how ketamine brings about rapid improvement in Obsessive-Compulsive Disorder (OCD) symptoms.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: University of Connecticut

Stanford Investigator(s):


  • Drug: Ketamine
  • Drug: Midazolam


Phase 2


Inclusion Criteria for participants with OCD:

   - age 18-65

   - Primary diagnosis of OCD

   - Sufficient severity of OCD symptoms

   - ability to tolerate a treatment-free period

   - capacity to provide informed consent

Inclusion criteria for healthy controls:

   - ages 18-65

   - capacity to provide informed consent

Exclusion criteria for participants with OCD:

   - Psychiatric or medical conditions that make participation unsafe

   - pregnant or nursing females

   - concurrent use of any medications that might increase the risk of participation (e.g.
   drug interactions)

   - presence of metallic device or dental braces

Exclusion criteria for healthy controls:

   - any current or lifetime psychiatric diagnosis

   - pregnant or nursing females

   - major medical or neurological problem

   - presence of metallic device or dental braces

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Elizabeth McCarthy